Last reviewed · How we verify
Palivizumab, motavizumab
Palivizumab, motavizumab is a Biologic drug developed by MedImmune LLC. It is currently in Phase 2 development.
At a glance
| Generic name | Palivizumab, motavizumab |
|---|---|
| Sponsor | MedImmune LLC |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children (PHASE3)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children (PHASE1, PHASE2)
- Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season (PHASE2)
- A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Palivizumab, motavizumab CI brief — competitive landscape report
- Palivizumab, motavizumab updates RSS · CI watch RSS
- MedImmune LLC portfolio CI
Frequently asked questions about Palivizumab, motavizumab
What is Palivizumab, motavizumab?
Palivizumab, motavizumab is a Biologic drug developed by MedImmune LLC.
Who makes Palivizumab, motavizumab?
Palivizumab, motavizumab is developed by MedImmune LLC (see full MedImmune LLC pipeline at /company/medimmune-llc).
What development phase is Palivizumab, motavizumab in?
Palivizumab, motavizumab is in Phase 2.
Related
- Manufacturer: MedImmune LLC — full pipeline
- Compare: Palivizumab, motavizumab vs similar drugs
- Pricing: Palivizumab, motavizumab cost, discount & access